Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.
Connor Hall, Sarah M Troutman, Douglas K Price, William D Figg, Min H Kang
Index: Clin. Genitourin. Cancer 11(1) , 10-9, (2013)
Full Text: HTML
Abstract
Overexpression of antiapoptotic B-cell lymphoma (Bcl-2) proteins confers the dysregulation of apoptosis and results in drug resistance in a variety of cancers, including those of the genitourinary tract. Inhibitors that target prosurvival Bcl-2 proteins are in preclinical and clinical development. The objective of this review is to assess the involvement of Bcl-2 proteins as well as the preclinical and clinical activity of Bcl-2 inhibitors under evaluation for genitourinary neoplasms.PubMed was used with both medical subject heading terms and free search to identify the relevant literature. Information on clinical trials was obtained using http://Clincaltrials.gov, EU Clinical Trials Register, and meeting abstracts of the American Society of Clinical Oncology.To date, 2 Bcl-2 inhibitors have been evaluated in clinical trials for genitourinary tumors (oblimersen and AT-101 (R-(-)-gossypol)). Both agents demonstrated some success in early stages of development, but their clinical activity did not meet expectations. Preclinical studies are under way for other Bcl-2 inhibitors including ABT-737, HA14-1, and Bcl-2 homology 3 inhibitors.Antiapoptotic Bcl-2 proteins are potential molecular targets in genitourinary cancers. Bcl-2 inhibitors might be effective as single agents or in combination with conventional therapies. However, the biology of the Bcl-2 family in genitourinary cancers remains poorly understood and robust preclinical studies are needed to inform clinical development. Such studies should aim to identify: (1) pharmacodynamic markers that could help guide patient selection for treatment with Bcl-2 inhibitors, and (2) optimal combinations of Bcl-2 inhibitors with other anticancer agents for future clinical investigation.Published by Elsevier Inc.
Related Compounds
Related Articles:
Male contraception: history and development.
2014-02-01
[Urol. Clin. North Am. 41(1) , 145-61, (2014)]
2014-04-01
[Br. J. Haematol. 165(1) , 78-88, (2014)]
2013-03-01
[Anticancer Res. 33(3) , 949-55, (2013)]
Di(phenylpropylamino)gossypol: a derivative of the dimeric natural product gossypol.
2013-04-01
[Acta Crystallogr. C 69(Pt 4) , 439-43, (2013)]
2013-11-01
[Leukemia 27(11) , 2262-4, (2013)]